HY-145944-5mg
|
MedChemexpress LLC
|
ASR-488 [CAS 2690312-65-1]
|
|
|
|
HY-145944-50mg
|
MedChemexpress LLC
|
ASR-488 [CAS 2690312-65-1]
|
|
|
|
HY-D0938-10mg
|
MedChemexpress LLC
|
CFDA-SE [CAS 150347-59-4]
|
|
|
|
HY-D0938-5mg
|
MedChemexpress LLC
|
CFDA-SE [CAS 150347-59-4]
|
|
|
|
HY-N7058-100mg
|
MedChemexpress LLC
|
cis-?Jasmone [CAS 488-10-8]
|
|
|
|
HY-N7058-500mg
|
MedChemexpress LLC
|
cis-?Jasmone [CAS 488-10-8]
|
|
|
|
HY-N3686-1g
|
MedChemexpress LLC
|
D-Arabitol [CAS 488-82-4]
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-N3686-100mg
|
MedChemexpress LLC
|
D-Arabitol [CAS 488-82-4]
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-N3686-1mL
|
MedChemexpress LLC
|
D-Arabitol [CAS 488-82-4] (10mM in DMSO)
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-135751-5mg
|
MedChemexpress LLC
|
Holomycin [CAS 488-04-0]
|
|
|
|
HY-R01462A-20nmol
|
MedChemexpress LLC
|
hsa-miR-488-3p agomir
|
|
|
|
HY-R01462A-5nmol
|
MedChemexpress LLC
|
hsa-miR-488-3p agomir
|
|
|
|
HY-RI01462A-20nmol
|
MedChemexpress LLC
|
hsa-miR-488-3p antagomir
|
|
|
|
HY-RI01462A-5nmol
|
MedChemexpress LLC
|
hsa-miR-488-3p antagomir
|
|
|
|
HY-RI01462-20nmol
|
MedChemexpress LLC
|
hsa-miR-488-3p inhibitor
|
|
|
|
HY-RI01462-5nmol
|
MedChemexpress LLC
|
hsa-miR-488-3p inhibitor
|
|
|
|
HY-R01462-20nmol
|
MedChemexpress LLC
|
hsa-miR-488-3p mimic
|
|
Cancer-programmed cell death
|
|
HY-R01462-5nmol
|
MedChemexpress LLC
|
hsa-miR-488-3p mimic
|
|
Cancer-programmed cell death
|
|
HY-R01463A-20nmol
|
MedChemexpress LLC
|
hsa-miR-488-5p agomir
|
|
|
|
HY-R01463A-5nmol
|
MedChemexpress LLC
|
hsa-miR-488-5p agomir
|
|
|
|
HY-RI01463A-20nmol
|
MedChemexpress LLC
|
hsa-miR-488-5p antagomir
|
|
|
|
HY-RI01463A-5nmol
|
MedChemexpress LLC
|
hsa-miR-488-5p antagomir
|
|
|
|
HY-RI01463-20nmol
|
MedChemexpress LLC
|
hsa-miR-488-5p inhibitor
|
|
|
|
HY-RI01463-5nmol
|
MedChemexpress LLC
|
hsa-miR-488-5p inhibitor
|
|
|
|
HY-R01463-20nmol
|
MedChemexpress LLC
|
hsa-miR-488-5p mimic
|
|
Cancer-programmed cell death
|
|